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Abstract
Our objective was to provide demographic profiles and incidence estimates of amyotrophic lateral 
sclerosis (ALS) in two diverse California metropolitan areas: Los Angeles County (LA) and the 
San Francisco Bay Area (SFBA). Data were retrospectively collected from multiple sources. Case 
eligibility criteria included residency in SFBA or LA, and treatment for or diagnosis of ALS 
between 1 January 2009 and 31 December 2011. Overall incidence rates as well as age-, gender-, 
race- and ethnicity-specific rates were calculated. We identified 539 ALS cases in SFBA and 545 
in LA; 618 were incident cases. Cases were more likely to be male and white. There were 
considerably more cases (p < 0.05) in LA who were foreign-born (LA, 22%; SFBA, 15%), black 
(LA, 10%; SFBA, 6%) or Hispanic (LA, 19%; SFBA, 10%). Conversely, the age adjusted 
incidence rates (per 100,000) were higher in SFBA for whites (LA, 1.40; SFBA, 2.49) and 
Hispanics (LA, 0.66; SFBA, 1.57) compared with LA. General case demographics and incidence 
rates in these two areas were similar to published studies. However, the differences between the 
two areas raise questions about how factors such as geography, access to care, and referral patterns 
may affect case ascertainment and diagnosis.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is the most 
common motor neuron disease and is characterized by progressive deterioration of upper 
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and lower motor neurons. ALS is age related, with the highest rate of onset between 55 and 
75 years (1,2). The average survival time after symptom onset is 2–5 years; only a small 
percentage of patients survive beyond five years (1,2). Males have a slightly higher 
prevalence than females (1–3). Little is known about the etiology of ALS; only 5–10% can 
be attributed to family history, leaving many questions about possible environmental factors 
(1–4).
The annual incidence rate of ALS in the United States is estimated to be 1.6–2.0 per 100,000 
population (5). Subpopulation incidence and prevalence rates for ALS are difficult to find 
due to the lack of representative data. The majority of ALS epidemiologic studies have 
focused on racially and ethnically homogenous population samples in Europe and non-
Western countries. Among these, there is relatively uniform incidence among white 
populations and a lower incidence among African, Asian, and Hispanic populations. 
However, it is difficult to compare ALS estimates across these studies and populations due 
to different case-finding methodologies (1,6–12).
In 2008, the U.S. Congress mandated that the Centers for Disease Control and Prevention 
(CDC) establish the National ALS Registry with the primary goal of determining national 
incidence and prevalence rates for ALS (13). The CDC's sister public health agency, the 
Agency for Toxic Substances and Disease Registry (ATSDR), created and maintains the 
registry. To validate the completeness and accuracy of registry data, ATSDR funded three 
state and eight metropolitan-area surveillance projects. This manuscript focuses on 
ATSDR's collaboration with the California Environmental Health Tracking Program – at the 
California Department of Public Health – to conduct metropolitan-area surveillance projects 
in Los Angeles County (LA) and the San Francisco Bay Area (SFBA). Site-specific goals 
included obtaining incidence rates for LA and SFBA and improving understanding of the 
demographic characteristics of the ALS population.
Materials and methods
We conducted retrospective surveillance to identify ALS cases in SFBA and LA who were 
seen or diagnosed by a neurologist between 1 January 2009 and 31 December 2011. The 
project population consisted of residents from two metropolitan areas: five SFBA counties 
(Alameda, Contra Costa, San Mateo, San Francisco, and Solano Counties) in Northern 
California with a combined population of 4.5 million and LA County in Southern California 
with a population of 9.8 million. These areas were chosen for their racial and ethnic 
diversity. According to the U.S. Census (14), SFBA counties were 23% Asian, 9% black, 
and 50% white, while LA was 14% Asian, 9% black, and 50% white. Among these, 22% 
and 48% were Hispanic (or any race), respectively. Both areas were 51% female and 49% 
male.
Case ascertainment
Primary data collection—A comprehensive list of neurologists was compiled from 
physician lists provided by the ALS Association (ALSA), state medical board, and internet 
searches. ALSA facilitated initial contacts with ALS care centers and large referral centers. 
An ALS care center was defined as a specialty center if it was funded by the ALSA and the 
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Muscular Dystrophy Association, and large referral centers are practices that diagnosed or 
provided care for at least 50 ALS patients during the reporting period. Physicians from 
smaller practices were identified and contacted by project staff through mailings, phone 
calls, faxes, and office visits.
Project staff contacted practicing neurologists serving the catchment areas to determine 
whether ALS patients were treated in their facility, and how many patients met the case 
definition. Neurology office staff identified potential cases by searching electronic billing 
records, patient databases, or directly consulting with the neurologist. Patients were reported 
if they could be classified into one of the El Escorial criteria categories (15) by the 
neurologist using the patients' medical record. In some instances where the reporting 
neurologist felt strongly that a patient had ALS but could not be classified into one the El 
Escorial criteria categories, these patients were placed into the unclassifiable category (16).
Secondary data collection—Using California's Electronic Death Registration System 
(EDRS), project staff obtained records of all deaths among residents of SFBA or LA 
between 1 January 2009 and 31 December 2011. Staff identified decedents with ALS as one 
of the causes of death who had not been captured through primary data collection. Attending 
physicians listed on the death record were contacted to verify diagnosis and obtain an ALS 
case report.
Case definition
ALS cases meeting the El Escorial criteria, who resided in SFBA or LA and who were 
diagnosed or under the care of a neurologist between 1 January 2009 and 31 December 
2011, were eligible for reporting. Residence was determined by zip code of record.
Data collection and quality assurance
Office staff completed a standardized case report form by abstracting case demographics – 
race, ethnicity, country of birth, address, diagnosis, dementia status, and family history of 
ALS – from patient charts. Identifying data elements such as name, date of birth, and partial 
social security number (SSN) were collected to de-duplicate cases and to compare with the 
National ALS Registry data. We followed U.S. federal guidelines and recorded race and 
ethnicity separately (17). Patients with more than one race indicated in their medical charts 
were classified as mixed race. Date of diagnosis was the first date a neurologist noted the 
patient had ALS in the medical chart. Data were entered into a Microsoft Access database 
and ongoing quality control checks were conducted to ensure case reports and electronic 
data matched. Cases that matched others based on name, SSN, or date of birth were flagged 
for review. Duplicate reports and death data, when available, were merged to create 
complete data on each case as necessary. A unique record was created for each individual; 
duplicate reports were not included in the final datasets.
A sample, of approximately 15% of cases, was systematically selected for quality assurance. 
For the selected cases, neurologists were asked to complete a more detailed medical records 
verification form and submit a recent electromyogram (EMG) to ensure diagnostic accuracy. 
To verify diagnosis, the completed forms and EMGs were reviewed by a consulting 
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neurologist who specialized in the diagnosis and treatment of ALS. The consulting 
neurologist was blinded to the practice and neurologist reporting the case.
Statistical analysis
Age at symptom onset and diagnosis and time from symptom onset to diagnosis were 
calculated for complete records. χ2 or Fisher's tests as appropriate were used to assess 
differences between groups and oneway analysis of variance (ANOVA) to compare 
continuous variables. A p-value < 0.05 was considered significant.
Incident cases
Age adjusted incidence estimates were calculated by site (SFBA v. LA) including only cases 
with dates of initial diagnosis occurring from 1 January 2009 to 31 December 2011. Age-
specific, race, and ethnicity estimates were also calculated by site. For all rate calculations, 
cases and populations were stratified by 10-year age groups, with those older than 80 years 
of age constituting a single group; rates were standardized using the US 2000 Census 
population. Age-adjusted rates and confidence intervals were calculated using the protocol 
of Tiwari, Clegg, and Zhou (18), while standardized rate ratios between the LA and SFBA 
areas were calculated using the method found in Newman (19).
Data cleaning and statistical analyses were conducted using Microsoft Excel and SAS v9.3 
(Cary NC) (20). This project was approved by the Center for Disease Control and 
Prevention Institutional Review Board (IRB) and determined to be public health surveillance 
(rather than human subjects research), and therefore not requiring institutional review board 
review, by the California Committee for the Protection of Human Subjects.
Results
Using multiple data sources, we identified 95% of expected cases (5). A disproportionate 
number were from SFBA, where we identified 150% of expected cases (539/360) compared 
with LA where we identified 69% (545/785). Over half (57%) of the cases were incident 
cases with initial diagnosis occurring between 2009 and 2011 (SFBA, 288; LA, 330). All 12 
of the ALS care centers (four in SFBA and six in LA), and large referral centers (one in 
SFBA and one in LA) in both catchment areas participated, and 83% (77/93) of practices 
that reported seeing ALS patients submitted case reports.
Characteristics of reported cases
The distributions of ALS cases by gender, race, ethnicity, and US-born status for SFBA, LA, 
and combined areas are shown in Table I. Males represented the majority of the cases – 320 
(59%) and 302 (55%) in SFBA and LA, respectively. White cases made up 72% (390) in 
SFBA and 70% (379) in LA. LA had twice as many Hispanic cases as SFBA – 102 (19%) 
vs. 55 (10%). Both sites had substantial yet differing proportions of cases with race or 
ethnicity not reported (Table I). There were no differences in the percentage of cases with 
health insurance by geographic area; 98% of patients had at least one type of insurance (data 
not presented). There were significantly more foreign-born cases reported in LA (22%) than 
in SFBA (15%). Country of birth was missing in 25% of cases overall.
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Mean age at diagnosis was 62.2 years (range 14–94 years) in SFBA and 60.8 years (range 
14–90 years) in LA. There was a significant difference in the age of symptom onset between 
sites: 60.6 (range 13–94) years in SFBA and 58.8 (range 11–90) years in LA. Mean time 
from symptom onset to diagnosis was 21 months (range 0–36 months), while the median 
time was 12 months.
Familial history of ALS was indicated in 3% (17) and 4% (22) of cases in SFBA and LA, 
respectively. Cases with a diagnosis of dementia were reported in 34 (6%) in SFBA and 22 
(4%) in LA.
Characteristics of incident cases
There were 618 (SFBA, 288; LA, 330) patients diagnosed between 1 January 2009 and 31 
December 2011. The distribution of gender, race, ethnicity, country of birth, family history 
of ALS, and presence of a dementia diagnosis was similar to the full set of reported cases 
(Table I).
Among these cases, overall mean age at time of diagnosis was 63.7 years (range 17–92 
years), with 65.2 years (range 32–92 years) in SFBA and 62.4 years (range 17–90 years) in 
LA. Overall mean age at symptom onset was 61.9 years (range 17–92 years); 63.7 (range 
28–92 years) in SFBA and 60.4 years (range 17–90 years) in LA.
Incidence rate calculations
Overall crude incidence rate was 1.4 per 100,000 (SFBA and LA: 2.1 and 1.1, respectively, 
per 100,000). Overall age-adjusted incidence rate was 1.7 per 100,000. The age-adjusted 
incidence estimate was higher in SFBA (2.0; CI = 1.8–2.3) compared with LA (1.2; CI = 
1.0–1.3).
Age distribution of incident ALS was similar in both catchment areas, increasing with age 
until 80 years with the highest incidence among the 70–79 years age group (SFBA and LA: 
11.7 and 5.9, respectively) (Figure 1). Based on standardized rate ratios (SRRs), differences 
in age-specific incidence rates between SFBA and LA were largest among the older age 
groups (Table II).
Within SFBA, whites had a notably higher incidence (2.5; CI = 2.2–2.9) than Asians (1.0; 
CI = 0.7–1.4), with the rate for blacks lying between these two (1.5; CI = 0.9–2.4). This 
pattern was similar in LA, with the rate among whites 1.4, Asians 0.7, and blacks 1.0. In 
each area, estimates were slightly lower among Hispanics compared to non-Hispanics 
(SFBA: 1.6 (1.0–2.3) versus 1.9 (1.7–2.2)); LA: 0.7 (0.5–0.9) versus 1.0 (0.9–1.2)).
Quality assurance
One hundred sixty-four cases were selected for review by the consulting ALS specialist for 
diagnosis verification: 69% from ALS care and referral centers and 31% from other 
practices. All of the cases reviewed from the unclassifiable category were found to meet the 
El Escorial criteria for ALS. Among all the reviewed cases, four (2.4%) were classified as 
not ALS and excluded from the final case count.
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This surveillance exercise presents data on ALS patients from two diverse metropolitan 
areas using multiple data sources. The size and diversity of the sample allowed us to 
describe the epidemiology of ALS cases and to provide the most thorough estimates – with 
some limitations – to date in CA, specifically for SFBA and LA.
Demographic characteristics among identified cases such as age of onset, slightly higher 
proportion of males, and higher proportion of white cases are similar to existing literature 
(1–3). The percentage of familial ALS reported in this project ranged from 3% to 4%, which 
is slightly lower than the 5–10% of familial ALS frequently reported in the literature (4). In 
Chio et al.'s review, the mean reported time from onset to diagnosis was 9–15 months (1); 
our project found a much longer delay at 21 months. Among studies reporting the median, 
the time between onset and diagnosis was 9–12 months, which is similar to what was 
observed in our project (12 months) (3,21–24).
Incidence
The overall age-adjusted incidence rate is comparable to previously estimated rates in the 
U.S. and lower than the rates reported in Logroscino et al. (5,10,24–29). Incidence rates 
among white populations have consistently been higher than non-white; this likely explains 
the differences between the rates reported in Europe and the rates reported in the U.S. where 
a higher percentage of the population is non-white. The lower incidence rate could also be 
related to this project's retrospective design, which has been suggested can result in lower 
estimates compared to prospective studies (1). The European studies were largely 
prospective utilizing data from established registries (16,30–32).
Incidence rates increased with age, peaking at 70–79 years followed by a marked decline. 
This follows the general pattern found in Logroscino's pooled analysis of six European 
registries (33) and a recent systematic review of population based studies published globally 
(1).
Within our project, SFBA had a higher incidence rate than LA. Incidence of white cases was 
higher, and we found differences among specific race/ethnicities by region. Previous 
research has found conflicting results in racial and ethnic differences in national ALS 
incidence rates (6,24,25,34). We found that Asians had the lowest rates and had notably 
lower rates than whites in both regions. No differences were found between the incidence 
rates of whites and blacks, and Hispanics had a lower incidence in LA only.
It is important to understand the effect that missing data have on our race- and ethnicity-
specific rate estimates (Tables I, II and Figure 2). Because there is not an `unknown' 
category for race or ethnicity in the census data, our denominator values can be considered 
to be a more complete representation of populations in each racial or ethnic category than 
can our numerator values. Therefore, compared to our population-wide incidence estimates, 
our subgroup incidence estimates should be considered downwardly biased, particularly 
regarding ethnicity, and particularly for LA. Race- and ethnicity-specific SRRs are more 
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difficult to interpret because of higher rates of missing data in LA, which biases these 
estimates upwards.
The large number of cases with unknown race and ethnicity can partly be attributed to 
differences in the collection and categorization of race and ethnicity across providers (who 
often combined race and ethnicity) compared with the categories we used in our project 
(which separate race and ethnicity). With additional information unavailable, chart 
abstractors were not always able to fill in separate responses for race and ethnicity. Although 
the U.S. federal standards (17) state that Hispanic origin (ethnicity) and race (regardless of 
ethnicity) are distinct groupings and should be collected separately, these standards are not 
mandated outside of federal agencies and federally supported projects.
Different referral patterns were observed between sites. For example, in the SFBA, the 
majority of neurology practices referred suspected cases to the ALS care centers (all of 
which reported cases), while in LA fewer practices made these referrals, resulting in more 
practices to follow up with, and fewer patients with records maintained in centralized 
electronic record systems. This referral pattern may have disproportionately affected 
Hispanics in LA, where a larger percentage were foreign-born, and additional factors – such 
as language, culture and access – may have impacted the likelihood of seeking care at an 
ALS center. Reasons for the greater than expected number of cases in SFBA and the fewer 
than expected in LA are unclear; the differences may represent true incidence rates in 
populations with varying sociodemographics and unidentified risk factors. However, the 
differences may be a result of dissimilarities in health care systems, rates of insurance 
coverage, and/or access to medical care in the two distinct geographic regions. Further 
investigation into factors affecting case ascertainment is warranted.
Strengths and limitations
Two primary limitations should be considered when interpreting the findings: first, the likely 
under-ascertainment of ALS cases, which may have affected rate estimates for LA, 
particularly among Hispanics. Secondly, incomplete data on race/ethnicity may have 
underestimated subgroup incidence rates. This project also has several strengths. The 
intensive case ascertainment process yielded a high number of confirmed cases from a 
variety of clinical settings, unique to ALS surveillance efforts. Quality assurance methods 
were used to assure that neurologists were assigning the El Escorial criteria appropriately. 
Finally, analyses and incidence rates presented here allow for comparisons with similar 
studies and fill gaps in the literature.
Conclusions
In summary, we collected ALS case data from two metropolitan areas with ethnically 
diverse populations. These data suggest that overall ALS incidence appears to be 
comparable to recent publications. Future studies are needed to assess whether the 
demographic patterns found in our surveillance data represent true disease patterns.
Moreover, the differences in case ascertainment could inform future surveillance efforts by 
the National ALS Registry. The forthcoming results of the national ALS surveillance effort 
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(of which this project is one component) will be an important next step for better 
understanding the current epidemiology of ALS among the U.S. population.
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Age-specific incidence of ALS, SF Bay Area and Los Angeles counties, 2009–2011.
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Age-adjusted race and ethnicity specific incidence of ALS, SF Bay Area and Los Angeles 
counties, 2009–2011.
VALLE et al. Page 11

























VALLE et al. Page 12
Table I
Characteristics of ALS cases identified for San Francisco Bay Area (SFBA) and Los Angeles County (LA), 
2009–2011.
All cases (number (%)) Incident cases (number (%))
Characteristic SFBA LA SFBA LA
Total 539 545 288 330
Gender
 Males 320 (59.4) 302 (55.4) 170 (59.0) 185 (56.1)
 Females 219 (40.6) 243 (44.6) 118 (40.9) 145 (43.9)
Race
 White 390 (72.4) 379 (69.5) 209 (72.6) 230 (69.7)
 Black 34 (6.3) 55 (10.1) 20 (6.9) 26 (7.9)
 Asian 64 (11.9) 46 (8.4) 35 (12.2) 30 (9.1)
 Other* 10 (1.9) 0 (0) 5 (1.7) 0 (0)
 Unknown 41 (7.6) 65 (11.9) 19 (6.6) 44 (13.3)
Ethnicity
 Hispanic 55 (10.2) 102 (18.7) 28 (9.7) 62 (18.8)
 Non-Hispanic 446 (82.8) 314 (57.6) 237 (82.3) 192 (58.2)
 Unknown 38 (7.0) 129 (23.7) 23 (8.0) 76 (23.0)
Country of Birth
 U.S. born 390 (72.3)** 222 (40.7)** 207 (71.9)** 130 (39.4)**
 Foreign born 78 (14.5)** 122 (22.4)** 44 (15.3)** 68 (20.6)**
 Unknown 71 (13.2)** 201 (36.9)** 37 (12.9)** 132 (40.0)**
Family history of ALS 17 (3.15) 22 (4.0) 10 (3.8) 15 (4.8)
 Dementia diagnosis 34 (6.3) 22 (4.0) 18 (6.3) 15 (4.7)
El Escorial criteria
 Definite, Probable, & Probable-lab supported 422 (78.3) 426 (78.2) 240 (83.3) 260 (78.8)
 Possible 110 (20.4) 71 (13.0) 43 (14.9) 45 (13.6)
 Unclassifiable 7 (1.3) 48 (8.8)** 5 (1.7) 25 (7.6)
Mean (Range)
 Age at diagnosis 62.2 [14y-94y] 60.8 [14y-90y] 65.2 [32–92y] 62.4 [17–90y]
 Age at symptom onset 60.6 [13y-94y]** 58.8 [11y-90y]** 63.7 [28–92y] 60.4 [17–90y]
*
Other includes those of mixed race.
**
Significant at p-value of 0.05 (SFBA vs. LA).
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Table II
Age-standardized incidence estimates and standardized rate ratios (SRR) for San Francisco Bay Area (SFBA) 
and Los Angeles County (LA), 2009–2011.
Characteristic SFBA Rate per 100,000 (95% CI) LA Rate per 100,000 (95% CI) SRR Rate per 100,000 (95% CI)
Total 2.01 (1.8–2.3) 1.17 (1.0–1.3) 1.72 (1.47–2.0)
Gender
 Males 2.60 (2.2–3.0) 1.40 (1.2–1.6) 1.80 (1.7–2.0)
 Females 1.50 (1.3–1.8) 1.00 (0.8–1.1) 1.60 (1.5–1.7)
Age group, years*
 30–39 0.30 (0.1–0.7) 0.23 (0.1–.0.4) 1.28 (0.4–4.2)
 40–49 1.27 (0.8–1.9) 0.96 (0.7–1.3) 1.33 (0.8–2.3)
 50–59 3.22 (2.5–4.2) 2.04 (1.6–2.6) 1.58 (1.1–2.3)
 60–69 6.99 (5.6–8.6) 3.95 (3.2–4.9) 1.77 (1.3–2.4)
 70–79 11.71 (9.3–14.6) 5.94 (4.7–7.4) 1.97 (1.4–2.7)
 80+ 6.39 (4.3–9.1) 3.18 (2.1–4.5) 2.01 (1.2–3.4)
Race**
 White 2.49 (2.2–2.9) 1.4 (1.2–1.6) 1.51 (0.9–2.5)
 Black 1.52 (0.9–2.4) 1.03 (0.7–1.5) 1.47 (0.8–2.7)
 Asian 1.00 (0.7–1.4) 0.66 (0.5–0.9) 1.78 (1.5–2.2)
Ethnicity
 Hispanic 1.57 (1.0–2.3) 0.66 (0.5–0.9) 2.38 (1.5–3.8)
 Non-Hispanic 1.89 (1.7–2.2) 1.01 (0.9–1.2) 1.88 (1.5–2.3)
*
Counts for incident cases under 30 years of age were insufficient to calculate rates.
**
Due to missing race and ethnicity data, actual incidence rates are likely higher and SRRs are likely lower than presented.
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